Actinogen Medical Limited (ASX:ACWOC)

Australia · Delayed Price · Currency is AUD · Option

0.0230

+0.0050 (27.78%)

At close: Jun 19, 2026

109.09% (1Y)

Market Cap	98.44M +34.4%
Revenue (ttm)	5.49M -44.7%
Net Income	-14.73M
EPS	-0.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	50,000
Open	0.0230
Previous Close	0.0180
Day's Range	0.0230 - 0.0230
52-Week Range	0.0070 - 0.0340
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 23, 2025

About Actinogen Medical

Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11β-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer’s disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen ... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 1999

Employees 6

Stock Exchange Australian Securities Exchange

Ticker Symbol ACWOC

Full Company Profile